Research desk · SLS · Nasdaq

SEC financials, peer compare, and chart. Scores open the matching desk. Research only — not advice.

SELLAS Life Sciences Group, Inc. · Pharmaceutical Preparations

SELLAS Life Sciences Group, Inc. financial statements, chart, and peer compare from SEC filings.

SELLAS Life Sciences Group, Inc. (SLS) discovers, develops, or markets pharmaceutical products.

Market cap
$2.89B
P/E
-49.40
Op. margin
—
Profit margin
—
FCF margin
—
ROE
-23.44%

Related Health Care stocks: TRVI stock financials · CRVS stock financials · TYRA stock financials · AMLX stock financials · JBIO stock financials

See Health Care moving on the anomaly desk

misprise.com
Watch / incomplete (<60) TTM Updated October 18, 2026 10:37 pm ← Screener
Primary research · 02

SLS financial statements

Each Compare name is its own block of years. Filing lines are SEC reports; P/E and price sit on that name’s TTM column only.

Primary research · 03

SLS stock peer compare

Each bar is that name’s percent vs its last TTM, on one zero line. Zero is unchanged. This ticker is the black bar.

Focus chart

Zero is unchanged vs last TTM. Every name is a percent for the metric you pick.

Supporting · 04

SLS stock peer headlines

Yahoo Finance RSS for SLS and the names in Compare.

Ticker Date Headline
Loading headlines…
Supporting · 05

SLS stock price chart

Overlays follow the Compare table.

Chart loads when you scroll here
Supporting · 06

SLS stock — research snapshot

Screen strengths and watchouts for SLS stock from the latest Misprise snapshot.

Strengths

  • Debt/equity 0.00 — leverage looks manageable.
  • Current ratio 18.83 — liquidity cushion.

Watchouts

  • ROA -22.2% — muted asset returns.
  • ROE -23.4% — soft equity returns.
  • EPS CAGR negative — earnings trajectory is soft.
  • Rev CAGR 5Y —
  • Rev CAGR 3Y —
  • EPS CAGR 5Y -34.7%
  • EPS CAGR 3Y -14.0%
  • FCF CAGR 5Y 22.2%
  • FCF CAGR 3Y 44.5%
Supporting · 07

SLS stock FAQs

Short answers for SLS stock — statements, sector, and how this page is meant to be used.

What is SLS stock?

SELLAS Life Sciences Group, Inc. (SLS) discovers, develops, or markets pharmaceutical products. SLS stock sits in Health Care (Pharmaceutical Preparations), listed on Nasdaq.

Where can I find SELLAS Life Sciences Group, Inc. financial statements?

SELLAS Life Sciences Group, Inc. financial statements — income statement, balance sheet, and cash flow — are on this SLS stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.

What happened to SLS stock?

This page is a research snapshot of SELLAS Life Sciences Group, Inc. (SLS) from the latest SEC filings in the Misprise database as of TTM. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.

Does this page show the SLS stock price?

The live chart on this SLS stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.

What sector is SLS stock in?

SELLAS Life Sciences Group, Inc. is classified in Pharmaceutical Preparations, inside the Health Care sector, and trades on Nasdaq. This page is a research snapshot, not a full company profile.

How do I read SLS financial statements?

Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.

Where does the SLS statement data come from?

Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.

Where can I find the SLS income statement, balance sheet, and cash flow?

On this SLS stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.

What is the Misprise Score for SLS stock?

SLS stock currently scores 0/100 (Watch / incomplete (<60)). SELLAS Life Sciences Group, Inc. scores weaker or incomplete on durable growth/quality inputs — leverage, coverage, and recent results deserve extra scrutiny. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.

How is the SLS comparison winner decided?

Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.

What is the Anomaly Score on this SLS page?

Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.

What does the green grant dot mean on SLS stock?

A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.

Is SLS stock a buy?

No recommendation either way. This SLS stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell SELLAS Life Sciences Group, Inc..